Added to YB: 2024-06-06
Pitch date: 2024-04-13
ADPT [bullish]
Adaptive Biotechnologies Corporation
+412.96%
current return
Author Info
No bio for this author
Company Info
Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases.
Market Cap
$2.1B
Pitch Price
$3.01
Price Target
N/A
Dividend
N/A
EV/EBITDA
-46.83
P/E
-25.97
EV/Sales
8.29
Sector
Life Sciences Tools and Services
Category
value
Aristotle Atlantic Focus Growth Strategy Portfolio Holding: Adaptive Biotechnologies Corporation
ADPT: Adaptive Bio to keep MRD diagnostic & immune medicine biz after strategic review, seeing more value in MRD once profitable. Targeting EBITDA breakeven in late 2025, cash flow breakeven in 2026. Q1 revenue beat consensus by ~9%. Believe stock trading at low valuation with strong potential.
Read full article (1 min)